Recordati reveals EMEA’s positive opinion of Silodyx and Urorec

Recordati revealed this week that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended the granting of marketing authorisation for its drug brands Urorec and Silodyx.

This applies to 4 mg and 8 mg hard-capsule doses respectively for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Silodyx, which was originally developed by Kissei Pharmaceuticals, has been obtained under license by Recordati for the whole of Europe and for a further 18 nations in the Middle East and Africa.

The active substance in both products is silodosin – a urological medicinal product – which is a selective antagonist of the alfa 1A-adrenoreceptors.

Last month, Recordati revealed that its pharmaceutical revenues rose by 10.4 per cent during the first nine months of 2009.

Its consolidated revenue for the period reached 556.2 million euros (498.7 million pounds).